SIEGFRIED: Added to the sample portfolio!

On February 20, the contract pharmaceutical manufacturer SIEGFRIED presented impressive financial results for 2025 and once again confirmed the high quality of its business model. All key targets were met, and the company achieved profitable growth despite a challenging market environment and negative currency effects. This was driven by the consistent implementation of its strategy, high operational efficiency, and strong positioning in attractive pharmaceutical markets. The solid balance sheet, strong cash flow, and broadly diversified product portfolio are particularly encouraging. More than 90% of revenue comes from products already on the market, ensuring high visibility and stability. In addition, SIEGFRIED has strategically rejuvenated its product portfolio and is likely to benefit from additional growth and further margin improvement in the coming years. The combination of financial strength, attractive growth prospects, and a valuation that is reasonable by industry standards convinces us! After recommending the stock for purchase at CHF 73 on May 28, we bought the first 5 shares for the model portfolio on June 15. The “surreal” downgrade by UBS the following day created unexpected pressure. We therefore issued an ad hoc announcement on June 17 to report that we had added another 5 shares at CHF 66.40. Given the promising outlook, we see attractive upside potential for the coming months and are therefore setting the price target at CHF 96!

SIEGFRIED HLDG N is listed on the SIX Swiss Exchange under the symbol SFZN; the security number is 142,932,682, and the last price was approximately CHF 67.95.